Drug Topics
FEBRUARY 12, 2025
Those who contributed to the arrest of Luigi Mangione, the suspect in the murder of UnitedHealthcare CEO Brian Thompson, are facing unjustified backlash. They are heroesnot snitches.
IDStewardship
FEBRUARY 12, 2025
In this article an infectious diseases pharmacist discusses important information to know about antibiotic minimum inhibitory concentrations. Authored By: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP Article posted12 February 2024 An antibiotic’s minimum inhibitory concentrations (MIC) is the lowest drugconcentration that prevents visible growth of a standard inoculum of a microorganism after ~24 hours of incubation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
FEBRUARY 12, 2025
Crystal Zhou, PharmD, APh, AHSCP, BCACP, discussed her role as Lead Pharmacist of the Cut Hypertension Program.
STAT
FEBRUARY 12, 2025
Where is DeepMind’s AI protein design spinout? The Alphabet-owned AI company took the biology world by storm in 2020 with AlphaFold2 , the protein structure prediction AI platform that “solved” a decades-old biology problem. In 2021, the company spun out Isomorphic Labs, an AI drug discovery company. But Isomorphic’s initial focus is on small-molecule drug discovery, with protein-based drugs remaining a distant twinkle in the company’s eye.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
FEBRUARY 12, 2025
Cardiovascular health is known to be associated with the probability of having active or developing migraine in the future.
PharmaVoice
FEBRUARY 12, 2025
As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
PharmD Live
FEBRUARY 12, 2025
As healthcare shifts toward value-based care, medication reconciliation has become a critical focus for reducing costs and improving patient outcomes. Discrepancies in medication regimens, particularly during care transitions like hospital discharge, are a leading cause of adverse drug events (ADEs). These preventable issues result in significant financial burdens on healthcare systems while compromising patient safety and care quality.
Drug Topics
FEBRUARY 12, 2025
The tablet formation of risdiplam (Evrysdi) demonstrates bioequivalence to the oral formulation of the drug.
PhRMA
FEBRUARY 12, 2025
Policies to contain health care costs by restricting access to medicines always come with the promise of making health care more affordable and reducing government spending. But what if they’re actually doing the opposite? A new study published in JAMA on Medicaid prescription denials exposes a harsh reality: denying access to medications doesn’t save Medicaid money, it’s shifting costs in a way that hurts both patients and taxpayers.
Drug Topics
FEBRUARY 12, 2025
For patients with atopic dermatitis reporting moderate-to-severe scratching, researchers explored the efficacy of an AI-enabled wearable sensor with closed-loop haptic feedback.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
FEBRUARY 12, 2025
Risdiplam is the only approved non-invasive disease-modifying SMA treatment.
Drug Topics
FEBRUARY 12, 2025
Multiple micronutrient supplements showed the greatest impact on reducing the risk of giving birth to small vulnerable newborns.
Fierce Healthcare
FEBRUARY 12, 2025
With budget reconciliation right around the corner, different slices of the healthcare industry have made their views clear on issues like physician pay, ACA subsidies, telehealth flexibilities, prior authorization, PBM reform and more.
Drug Topics
FEBRUARY 12, 2025
The designation is based on the AMULET phase 2 trial, which was the first-in-human study of the drug.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
PhRMA
FEBRUARY 12, 2025
A new report explains the flow of dollars through the pharmaceutical supply chain for commercially insured patients taking retail medicines and details how transactions between stakeholders affect patient costs at the pharmacy counter. The report also highlights how the 340B hospital markup program and increased consolidation and vertical integration among supply chain entities raises the cost of medicines for patients and employers.
Drug Topics
FEBRUARY 12, 2025
Data has shown the investigational cell therapy is well-tolerated in patients and showed preliminary impacts on cognition.
Pharmacy Times
FEBRUARY 12, 2025
Reductions in cerebellar volume were associated with cognitive deficits and lower kidney function in those with CKD.
Pharmaceutical Technology
FEBRUARY 12, 2025
Merck acquisition target SpringWorks will go toe-to-toe with AstraZeneca in the US neurofibromatosis market.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
FEBRUARY 12, 2025
UnitedHealth Group and Amedisys outlined plans to divest a significant number of home health and hospice locations as they seek to close their $3.3 billion merger.
Pharmacy Times
FEBRUARY 12, 2025
The trend toward higher-potency marijuana could pose additional, unknown risks.
Fierce Healthcare
FEBRUARY 12, 2025
The partnership will allow Forge patients to get on PrEP if they are interested and eligible. Patients must be commercially insured or on Medicare to qualify for TBD services.
Pharmacy Times
FEBRUARY 12, 2025
The approval follows the ECHELON-3 study, which enrolled adults with relapsed or refractory large B-cell lymphoma.
Fierce Healthcare
FEBRUARY 12, 2025
Apple is broadening its health research ambitions to use its devices, including iPhones, Apple Watch and AirPods, for a longitudinal, virtual study to monitor changes in participants health.
pharmaphorum
FEBRUARY 12, 2025
Merck KGaA is talking to SpringWorks about a takeover, and FDA approval for a neurofibromatosis drug could have sweetened any potential deal.
Fierce Healthcare
FEBRUARY 12, 2025
Most employers reported being concerned about the rising cost of fertility care. Nearly two-thirds are planning to add preconception coverage in the next year. More than half also plan to enhance or add fertility support in the next year.
Pharmacy Times
FEBRUARY 12, 2025
Diversity in clinical trials remains important to ensure research data for therapies accurately reflects the diverse patient populations who will use them globally.
pharmaphorum
FEBRUARY 12, 2025
Abcuro has raised $200m in financing that should allow it to complete a pivotal trial of ulviprubart for rare disease inclusion body myositis (IBM).
Fierce Healthcare
FEBRUARY 12, 2025
CVS Health reported $1.6 billion in profit for the fourth quarter, down from a $2 billion haul a year ago, according to its earnings report released Wednesday.
pharmaphorum
FEBRUARY 12, 2025
BridgeBio and Bayer are poised to challenge Pfizer's Vyndaqel in the EU after acoramidis gets a green light for ATTR cardiomyopathy.
Pharmacy Times
FEBRUARY 12, 2025
Duloxetine offers treatment for various neuro-psychiatric and pain disorders in patients who have difficulty swallowing.
pharmaphorum
FEBRUARY 12, 2025
An e-Book aimed at children with rare kidney disease aHUS can help them understand the condition, deal with emotions, and find support, says Alexion.
Pharmacy Times
FEBRUARY 12, 2025
Donna Ryan explains why long-term treatment with GLP-1 medication is typically necessary to maintain weight loss benefits.
Pharmaceutical Technology
FEBRUARY 12, 2025
GlobalDatas Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.
Expert insights. Personalized for you.
465 
Let's personalize your content